154 related articles for article (PubMed ID: 32715441)
21. Evidence of associations of APOBEC3B gene deletion with susceptibility to persistent HBV infection and hepatocellular carcinoma.
Zhang T; Cai J; Chang J; Yu D; Wu C; Yan T; Zhai K; Bi X; Zhao H; Xu J; Tan W; Qu C; Lin D
Hum Mol Genet; 2013 Mar; 22(6):1262-9. PubMed ID: 23213177
[TBL] [Abstract][Full Text] [Related]
22. Hypoxia-Inducible Factor 1 Alpha-Mediated RelB/APOBEC3B Down-regulation Allows Hepatitis B Virus Persistence.
Riedl T; Faure-Dupuy S; Rolland M; Schuehle S; Hizir Z; Calderazzo S; Zhuang X; Wettengel J; Lopez MA; Barnault R; Mirakaj V; Prokosch S; Heide D; Leuchtenberger C; Schneider M; Heßling B; Stottmeier B; Wessbecher IM; Schirmacher P; McKeating JA; Protzer U; Durantel D; Lucifora J; Dejardin E; Heikenwalder M
Hepatology; 2021 Oct; 74(4):1766-1781. PubMed ID: 33991110
[TBL] [Abstract][Full Text] [Related]
23. Expression of APOBEC3B mRNA in Primary Breast Cancer of Japanese Women.
Tokunaga E; Yamashita N; Tanaka K; Inoue Y; Akiyoshi S; Saeki H; Oki E; Kitao H; Maehara Y
PLoS One; 2016; 11(12):e0168090. PubMed ID: 27977754
[TBL] [Abstract][Full Text] [Related]
24. APOBEC3B deletion polymorphism and lung cancer risk in the southern Chinese population.
Ben X; Tian D; Liang J; Wu M; Xie F; Zheng J; Chen J; Fei Q; Guo X; Weng X; Liu S; Xie X; Ying Y; Qiao G; Jing C
Ann Transl Med; 2021 Apr; 9(8):656. PubMed ID: 33987354
[TBL] [Abstract][Full Text] [Related]
25. Endogenous APOBEC3B Overexpression Constitutively Generates DNA Substitutions and Deletions in Myeloma Cells.
Yamazaki H; Shirakawa K; Matsumoto T; Hirabayashi S; Murakawa Y; Kobayashi M; Sarca AD; Kazuma Y; Matsui H; Maruyama W; Fukuda H; Shirakawa R; Shindo K; Ri M; Iida S; Takaori-Kondo A
Sci Rep; 2019 May; 9(1):7122. PubMed ID: 31073151
[TBL] [Abstract][Full Text] [Related]
26. Genetic inhibitors of APOBEC3B-induced mutagenesis.
Mertz TM; Rice-Reynolds E; Nguyen L; Wood A; Cordero C; Bray N; Harcy V; Vyas RK; Mitchell D; Lobachev K; Roberts SA
Genome Res; 2023 Sep; 33(9):1568-1581. PubMed ID: 37532520
[TBL] [Abstract][Full Text] [Related]
27. Protein kinase A inhibits tumor mutator APOBEC3B through phosphorylation.
Matsumoto T; Shirakawa K; Yokoyama M; Fukuda H; Sarca AD; Koyabu S; Yamazaki H; Kazuma Y; Matsui H; Maruyama W; Nagata K; Tanabe F; Kobayashi M; Shindo K; Morishita R; Sato H; Takaori-Kondo A
Sci Rep; 2019 Jun; 9(1):8307. PubMed ID: 31165764
[TBL] [Abstract][Full Text] [Related]
28. Progressive APOBEC3B mRNA expression in distant breast cancer metastases.
Sieuwerts AM; Schrijver WA; Dalm SU; de Weerd V; Moelans CB; Ter Hoeve N; van Diest PJ; Martens JW; van Deurzen CH
PLoS One; 2017; 12(1):e0171343. PubMed ID: 28141868
[TBL] [Abstract][Full Text] [Related]
29. Immune inactivation by APOBEC3B enrichment predicts response to chemotherapy and survival in gastric cancer.
Xia S; Gu Y; Zhang H; Fei Y; Cao Y; Fang H; Wang J; Lin C; Zhang H; Li H; He H; Xu J; Li R; Liu H; Zhang W
Oncoimmunology; 2021; 10(1):1975386. PubMed ID: 34552824
[TBL] [Abstract][Full Text] [Related]
30. The role of APOBEC3B in lung tumor evolution and targeted cancer therapy resistance.
Caswell DR; Gui P; Mayekar MK; Law EK; Pich O; Bailey C; Boumelha J; Kerr DL; Blakely CM; Manabe T; Martinez-Ruiz C; Bakker B; De Dios Palomino Villcas J; I Vokes N; Dietzen M; Angelova M; Gini B; Tamaki W; Allegakoen P; Wu W; Humpton TJ; Hill W; Tomaschko M; Lu WT; Haderk F; Al Bakir M; Nagano A; Gimeno-Valiente F; de Carné Trécesson S; Vendramin R; Barbè V; Mugabo M; Weeden CE; Rowan A; McCoach CE; Almeida B; Green M; Gomez C; Nanjo S; Barbosa D; Moore C; Przewrocka J; Black JRM; Grönroos E; Suarez-Bonnet A; Priestnall SL; Zverev C; Lighterness S; Cormack J; Olivas V; Cech L; Andrews T; Rule B; Jiao Y; Zhang X; Ashford P; Durfee C; Venkatesan S; Temiz NA; Tan L; Larson LK; Argyris PP; Brown WL; Yu EA; Rotow JK; Guha U; Roper N; Yu J; Vogel RI; Thomas NJ; Marra A; Selenica P; Yu H; Bakhoum SF; Chew SK; Reis-Filho JS; Jamal-Hanjani M; Vousden KH; McGranahan N; Van Allen EM; Kanu N; Harris RS; Downward J; Bivona TG; Swanton C
Nat Genet; 2024 Jan; 56(1):60-73. PubMed ID: 38049664
[TBL] [Abstract][Full Text] [Related]
31. DHX9 interacts with APOBEC3B and attenuates the anti-HBV effect of APOBEC3B.
Chen Y; Shen B; Zheng X; Long Q; Xia J; Huang Y; Cai X; Wang D; Chen J; Tang N; Huang A; Hu Y
Emerg Microbes Infect; 2020; 9(1):366-377. PubMed ID: 32056513
[TBL] [Abstract][Full Text] [Related]
32. m6A demethylation of cytidine deaminase APOBEC3B mRNA orchestrates arsenic-induced mutagenesis.
Gao M; Qi Z; Feng W; Huang H; Xu Z; Dong Z; Xu M; Han J; Kloeber JA; Huang J; Lou Z; Liu S
J Biol Chem; 2022 Feb; 298(2):101563. PubMed ID: 34998823
[TBL] [Abstract][Full Text] [Related]
33. APOBEC3B coordinates R-loop to promote replication stress and sensitize cancer cells to ATR/Chk1 inhibitors.
Zong C; Zhang Z; Gao L; He J; Wang Y; Li Q; Liu X; Yang J; Chen D; Huang R; Zheng G; Jin X; Wei W; Jia R; Shen J
Cell Death Dis; 2023 Jun; 14(6):348. PubMed ID: 37270643
[TBL] [Abstract][Full Text] [Related]
34. The therapeutic candidate for immune checkpoint inhibitors elucidated by the status of tumor-infiltrating lymphocytes (TILs) and programmed death ligand 1 (PD-L1) expression in triple negative breast cancer (TNBC).
Tomioka N; Azuma M; Ikarashi M; Yamamoto M; Sato M; Watanabe KI; Yamashiro K; Takahashi M
Breast Cancer; 2018 Jan; 25(1):34-42. PubMed ID: 28488168
[TBL] [Abstract][Full Text] [Related]
35. Integrative genomic analyses of APOBEC-mutational signature, expression and germline deletion of APOBEC3 genes, and immunogenicity in multiple cancer types.
Chen Z; Wen W; Bao J; Kuhs KL; Cai Q; Long J; Shu XO; Zheng W; Guo X
BMC Med Genomics; 2019 Sep; 12(1):131. PubMed ID: 31533728
[TBL] [Abstract][Full Text] [Related]
36. Characterization of the mechanism by which the RB/E2F pathway controls expression of the cancer genomic DNA deaminase APOBEC3B.
Roelofs PA; Goh CY; Chua BH; Jarvis MC; Stewart TA; McCann JL; McDougle RM; Carpenter MA; Martens JW; Span PN; Kappei D; Harris RS
Elife; 2020 Sep; 9():. PubMed ID: 32985974
[TBL] [Abstract][Full Text] [Related]
37. Effect of neoadjuvant chemotherapy on tumor-infiltrating lymphocytes and PD-L1 expression in breast cancer and its clinical significance.
Pelekanou V; Carvajal-Hausdorf DE; Altan M; Wasserman B; Carvajal-Hausdorf C; Wimberly H; Brown J; Lannin D; Pusztai L; Rimm DL
Breast Cancer Res; 2017 Aug; 19(1):91. PubMed ID: 28784153
[TBL] [Abstract][Full Text] [Related]
38. APOBEC3B promotes hepatocarcinogenesis and metastasis through novel deaminase-independent activity.
Ma W; Ho DW; Sze KM; Tsui YM; Chan LK; Lee JM; Ng IO
Mol Carcinog; 2019 May; 58(5):643-653. PubMed ID: 30575099
[TBL] [Abstract][Full Text] [Related]
39. Germline APOBEC3B deletion influences clinicopathological parameters in luminal-A breast cancer: evidences from a southern Brazilian cohort.
Vitiello GAF; de Sousa Pereira N; Amarante MK; Banin-Hirata BK; Campos CZ; de Oliveira KB; Losi-Guembarovski R; Watanabe MAE
J Cancer Res Clin Oncol; 2020 Jun; 146(6):1523-1532. PubMed ID: 32285256
[TBL] [Abstract][Full Text] [Related]
40. APOBEC3B interaction with PRC2 modulates microenvironment to promote HCC progression.
Wang D; Li X; Li J; Lu Y; Zhao S; Tang X; Chen X; Li J; Zheng Y; Li S; Sun R; Yan M; Yu D; Cao G; Yang Y
Gut; 2019 Oct; 68(10):1846-1857. PubMed ID: 31154396
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
